Literature DB >> 34169636

Assessing safety at the end of clinical trials using system organ classes: A case and comparative study.

Raymond Carragher1,2,3, Chris Robertson2,4.   

Abstract

Recent approaches to the statistical analysis of adverse event (AE) data in clinical trials have proposed the use of groupings of related AEs, such as by system organ class (SOC). These methods have opened up the possibility of scanning large numbers of AEs while controlling for multiple comparisons, making the comparative performance of the different methods in terms of AE detection and error rates of interest to investigators. We apply two Bayesian models and two procedures for controlling the false discovery rate (FDR), which use groupings of AEs, to real clinical trial safety data. We find that while the Bayesian models are appropriate for the full data set, the error controlling methods only give similar results to the Bayesian methods when low incidence AEs are removed. A simulation study is used to compare the relative performances of the methods. We investigate the differences between the methods over full trial data sets, and over data sets with low incidence AEs and SOCs removed. We find that while the removal of low incidence AEs increases the power of the error controlling procedures, the estimated power of the Bayesian methods remains relatively constant over all data sizes. Automatic removal of low-incidence AEs however does have an effect on the error rates of all the methods, and a clinically guided approach to their removal is needed. Overall we found that the Bayesian approaches are particularly useful for scanning the large amounts of AE data gathered.
© 2021 The Authors. Pharmaceutical Statistics published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Bayesian hierarchy; adverse events; false discovery rate; safety; system organ class

Mesh:

Year:  2021        PMID: 34169636     DOI: 10.1002/pst.2148

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  1 in total

1.  Leveraging Machine Learning to Facilitate Individual Case Causality Assessment of Adverse Drug Reactions.

Authors:  Yauheniya Cherkas; Joshua Ide; John van Stekelenborg
Journal:  Drug Saf       Date:  2022-05-17       Impact factor: 5.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.